151 related articles for article (PubMed ID: 20557463)
1. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States.
Kim A; Nicolau DP; Kuti JL
Mycoses; 2011 Sep; 54(5):e301-12. PubMed ID: 20557463
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
Selleslag D; Vogelaers D; Marbaix S
Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
[TBL] [Abstract][Full Text] [Related]
5. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis.
Lewis JS; Boucher HW; Lubowski TJ; Ambegaonkar AJ; Day DL; Patterson TF
Pharmacotherapy; 2005 Jun; 25(6):839-46. PubMed ID: 15927903
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
Clemons KV; Schwartz JA; Stevens DA
Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia.
Chabrol A; Cuzin L; Huguet F; Alvarez M; Verdeil X; Linas MD; Cassaing S; Giron J; Tetu L; Attal M; Récher C
Haematologica; 2010 Jun; 95(6):996-1003. PubMed ID: 20007135
[TBL] [Abstract][Full Text] [Related]
8. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach.
Ananda-Rajah MR; Cheng A; Morrissey CO; Spelman T; Dooley M; Neville AM; Slavin M
Antimicrob Agents Chemother; 2011 May; 55(5):1953-60. PubMed ID: 21357302
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
Cesaro S; Toffolutti T; Messina C; Calore E; Alaggio R; Cusinato R; Pillon M; Zanesco L
Eur J Haematol; 2004 Jul; 73(1):50-5. PubMed ID: 15182338
[TBL] [Abstract][Full Text] [Related]
11. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
12. Cerebral aspergillosis in the critically ill: two cases of successful medical treatment.
Ehrmann S; Bastides F; Gissot V; Mercier E; Magro P; Bailly E; Legras A
Intensive Care Med; 2005 May; 31(5):738-42. PubMed ID: 15782314
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic assessment of therapy for invasive aspergillosis.
Luong ML; Husain S; Rotstein C
Mycoses; 2013 May; 56(3):338-49. PubMed ID: 23311989
[TBL] [Abstract][Full Text] [Related]
14. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
Garbino J; Schnetzler G; Roberts C
Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.
Karthaus M
Eur J Med Res; 2011 Apr; 16(4):145-52. PubMed ID: 21486728
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher PJ
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
[No Abstract] [Full Text] [Related]
20. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]